1/24
05:10 am
telo
Telomir Pharmaceuticals (NASDAQ:TELO) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Telomir Pharmaceuticals (NASDAQ:TELO) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
1/13
04:06 pm
telo
Telomir Pharmaceuticals (NASDAQ:TELO) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating on the stock.
Low
Report
Telomir Pharmaceuticals (NASDAQ:TELO) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating on the stock.
1/5
08:06 am
telo
Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models [Yahoo! Finance]
High
Report
Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models [Yahoo! Finance]